The Australian article on BTA was very informative regarding the...

The Australian article on BTA was very informative regarding the history of developing Relenza but it won't do anything for the share price which will struggle to get back over $2.20. It is way overvalued and the company is still reluctant to discuss the financial benefits they will gain from increased Relenz sales. It is quite clear that they do not want to improve financial transparency as they know the current Market Cap cannot be justified by fundamentals.

Coop